Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 40 | 2025 | 459 | 6.070 |
Why?
|
| Endoscopy | 9 | 2011 | 56 | 2.080 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2021 | 15 | 1.760 |
Why?
|
| Mammary Glands, Human | 6 | 2011 | 19 | 1.670 |
Why?
|
| Mastectomy, Segmental | 8 | 2021 | 18 | 1.460 |
Why?
|
| Mastectomy | 5 | 2024 | 21 | 0.870 |
Why?
|
| Breast | 7 | 2021 | 52 | 0.780 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2011 | 9 | 0.750 |
Why?
|
| Female | 41 | 2025 | 15156 | 0.720 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 2021 | 0.710 |
Why?
|
| Medicare | 2 | 2024 | 124 | 0.580 |
Why?
|
| Humans | 43 | 2025 | 28097 | 0.540 |
Why?
|
| Aged | 17 | 2024 | 5400 | 0.530 |
Why?
|
| Middle Aged | 20 | 2025 | 7138 | 0.510 |
Why?
|
| Microwaves | 3 | 2009 | 10 | 0.440 |
Why?
|
| Exosomes | 3 | 2025 | 96 | 0.430 |
Why?
|
| Nipples | 4 | 2009 | 5 | 0.420 |
Why?
|
| Adult | 16 | 2022 | 7740 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 330 | 0.400 |
Why?
|
| Hyperthermia, Induced | 2 | 2009 | 30 | 0.380 |
Why?
|
| Medicaid | 1 | 2011 | 54 | 0.360 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 62 | 0.360 |
Why?
|
| Therapeutic Irrigation | 4 | 2005 | 19 | 0.350 |
Why?
|
| Brachytherapy | 1 | 2011 | 51 | 0.350 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 1 | 0.340 |
Why?
|
| Cosmetics | 1 | 2010 | 3 | 0.340 |
Why?
|
| General Surgery | 1 | 2011 | 55 | 0.340 |
Why?
|
| Mammaplasty | 1 | 2010 | 12 | 0.340 |
Why?
|
| Medical Oncology | 1 | 2011 | 94 | 0.330 |
Why?
|
| Clinical Competence | 1 | 2011 | 229 | 0.320 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2010 | 72 | 0.310 |
Why?
|
| Prospective Studies | 7 | 2022 | 1248 | 0.290 |
Why?
|
| Hyperplasia | 3 | 2020 | 27 | 0.270 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 478 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2024 | 2546 | 0.270 |
Why?
|
| Mammography | 2 | 2010 | 79 | 0.260 |
Why?
|
| Prognosis | 5 | 2024 | 803 | 0.250 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2005 | 9 | 0.250 |
Why?
|
| Survival Rate | 3 | 2011 | 430 | 0.250 |
Why?
|
| Specimen Handling | 1 | 2005 | 33 | 0.240 |
Why?
|
| Histone Deacetylases | 1 | 2025 | 26 | 0.240 |
Why?
|
| SEER Program | 1 | 2024 | 47 | 0.230 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 27 | 0.230 |
Why?
|
| Repressor Proteins | 1 | 2025 | 118 | 0.230 |
Why?
|
| Postoperative Complications | 1 | 2009 | 611 | 0.220 |
Why?
|
| Surgicenters | 1 | 2002 | 1 | 0.200 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2002 | 6 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 73 | 0.200 |
Why?
|
| Mastitis | 1 | 2002 | 3 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 37 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2003 | 46 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2005 | 221 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2011 | 2379 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2016 | 301 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 36 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2021 | 5 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 33 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2011 | 237 | 0.170 |
Why?
|
| Butylene Glycols | 1 | 2020 | 4 | 0.170 |
Why?
|
| Glucosides | 1 | 2020 | 8 | 0.170 |
Why?
|
| Lignans | 1 | 2020 | 10 | 0.170 |
Why?
|
| Premenopause | 1 | 2020 | 20 | 0.170 |
Why?
|
| Young Adult | 4 | 2022 | 2733 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1013 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 300 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 405 | 0.150 |
Why?
|
| Endoscopes | 2 | 2011 | 7 | 0.140 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 1319 | 0.130 |
Why?
|
| United States | 3 | 2024 | 2146 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 465 | 0.120 |
Why?
|
| Biopsy | 2 | 2005 | 206 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 109 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 162 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 1 | 2015 | 105 | 0.110 |
Why?
|
| Risk Factors | 4 | 2024 | 2081 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 2 | 2024 | 33 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 48 | 0.100 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 8 | 0.090 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 24 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 125 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2025 | 276 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 769 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 25 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 47 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2009 | 27 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
| Spasm | 1 | 2009 | 4 | 0.080 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2009 | 3 | 0.080 |
Why?
|
| Lymphedema | 1 | 2009 | 15 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 330 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2025 | 331 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2009 | 34 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 104 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 43 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2015 | 1435 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 217 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2009 | 62 | 0.070 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 14 | 0.070 |
Why?
|
| Mice | 4 | 2025 | 4654 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 385 | 0.070 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 100 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 288 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 322 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2005 | 31 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2005 | 23 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 722 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2005 | 19 | 0.060 |
Why?
|
| Laser Therapy | 1 | 2005 | 30 | 0.060 |
Why?
|
| Office Visits | 1 | 2004 | 8 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2025 | 118 | 0.060 |
Why?
|
| Adolescent | 2 | 2022 | 3122 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 302 | 0.060 |
Why?
|
| Incidence | 1 | 2005 | 562 | 0.050 |
Why?
|
| Animals | 4 | 2025 | 10423 | 0.050 |
Why?
|
| Mastectomy, Radical | 1 | 2003 | 1 | 0.050 |
Why?
|
| Disease Progression | 1 | 2025 | 473 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2003 | 33 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 29 | 0.050 |
Why?
|
| Suction | 1 | 2003 | 10 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2005 | 612 | 0.050 |
Why?
|
| Papilloma | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 409 | 0.050 |
Why?
|
| Blood | 1 | 2002 | 34 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2002 | 51 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 56 | 0.050 |
Why?
|
| Home Care Services | 1 | 2002 | 37 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 17 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 199 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2015 | 352 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 96 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2001 | 12 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2002 | 193 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 143 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 1592 | 0.050 |
Why?
|
| Mass Screening | 1 | 2002 | 152 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 371 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 521 | 0.040 |
Why?
|
| Hormones | 1 | 2021 | 43 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2020 | 22 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 60 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Flax | 1 | 2020 | 2 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 253 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 466 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 433 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 679 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 31 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 66 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 144 | 0.030 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2015 | 5 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 13 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 34 | 0.030 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 122 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 134 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 138 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 124 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 179 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 453 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 123 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2011 | 13 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2011 | 18 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1461 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 114 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 269 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 545 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 607 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 692 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 409 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 658 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 696 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 288 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 775 | 0.020 |
Why?
|
| Epirubicin | 1 | 2006 | 1 | 0.020 |
Why?
|
| Taxoids | 1 | 2006 | 37 | 0.020 |
Why?
|
| Male | 1 | 2021 | 13491 | 0.020 |
Why?
|
| Necrosis | 1 | 2004 | 85 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 202 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 7 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 137 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 214 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 248 | 0.010 |
Why?
|